Skip to main content
Start triage

Start triage first, then route to emergency care.

Need urgent help? Start triage first, then route to emergency care.

Roxee Meds Catalog

Marbofloxacin

Medication catalog facts with explicit FDA-approval, off-label, source-limited, and safety context.

Both Catalog complete FDA data linked Rx required Chewable tablet Multiple FDA labelers Official label facts Owner quick guide first

Veterinary professional?

Showing simplified owner view. Switch to Vet View for full technical detail.

Data freshness

Storefront facts
Catalog refreshed
May 5, 2026, 10:00 a.m.

These are the storefront facts Roxee uses on browse cards and quick facts.

FDA applications
FDA application data refreshed
May 5, 2026, 10:00 a.m.

Sponsor, product, and application records imported from Animal Drugs @ FDA.

Safety reports
Safety data refreshed
May 5, 2026, 10:01 a.m.

openFDA reaction terms and case summaries are supporting evidence, not proof of causality.

Source timing details
Source timing details
  • Storefront facts: Source Roxee | Refreshed May 5, 2026, 10:00 AM UTC
    The storefront fact projection used for browse cards and quick facts.
  • Animal Drugs @ FDA: Source FDA | Refreshed May 5, 2026, 10:00 AM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed May 5, 2026, 10:00 AM UTC
    Package/product NDCs from FDA’s electronic listing directory (XLS).
  • openFDA reaction terms: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC

Evidence

Reviewed / Updated / Sources

Reviewed by: Not available

Last reviewed: February 12, 2026

Updated: February 12, 2026, 10:44 PM UTC

Image coming soon
Marbofloxacin

Marbofloxacin

Drug type: Generic ingredient • Branded profile FDA branded products available

Both Chewable tablet Rx required 100% storefront ready

Species: Both

Manufacturer: Multiple FDA labelers

Medication Snapshot

Merged from the current Roxee medication system with field-level provenance, freshness, and completeness tracking.

Marbofloxacin

For the treatment of infections in dogs associated with bacteria susceptible to marbofloxacin. For the treatment of infections in cats associated with bacteria susceptible to marbofloxacin. For the treatment of otitis externa associated with susceptible strains of yeast ( Malassezia pachydermatis ) and bacteria ( Staphylococcus pseudintermedius ) in dogs. Species commonly shown: Both, Dog, No Use Class Stated Or Implied, Cat, No Use Class Stated Or Implied.

Generic name
Marbofloxacin
Brand names
Zeniquin®, Marboquin™, Marbofloxacin Chewable Tablets, Marbofloxacin
Manufacturer
Multiple FDA labelers
Species
Both, Dog, No Use Class Stated Or Implied, Cat, No Use Class Stated Or Implied
Dosage forms
Chewable tablet, Tablet, Chewable Tablets
Prescription
Prescription required
Completeness
100%
Validation
Complete
Brand names
Zeniquin® Marboquin™ Marbofloxacin Chewable Tablets Marbofloxacin Cronoquin™ Tablets Marboquin DELAQUIN FluoroFlox Zeniquin X
Dosage forms
Chewable tablet Tablet Chewable Tablets

Indications / Uses

For the treatment of infections in dogs associated with bacteria susceptible to marbofloxacin. For the treatment of infections in cats associated with bacteria susceptible to marbofloxacin. For the treatment of otitis externa associated with susceptible strains of yeast ( Malassezia pachydermatis ) and bacteria ( Staphylococcus pseudintermedius ) in dogs.

Warnings / Contraindications

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extra-label use of this drug in food-producing animals.

  • Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extra-label use of this drug in food-producing animals.

Side Effects

Top reported reactions (openFDA): Vomiting, Lethargy (see also Central nervous system depression in 'Neurological'), Lack of efficacy - NOS, Anorexia, Other abnormal test result NOS, Death by euthanasia.

FAQ

Both, Dog, No Use Class Stated Or Implied, Cat, No Use Class Stated Or Implied

Yes. Roxee shows this as prescription-only.

Chewable tablet, Tablet, Chewable Tablets

Source Transparency

Add to My Pet's Meds

Choose a pet, confirm current or past, and optionally add reminder notes.

Sign in to save this medication to your pet profile.

Sign in to continue

Pet Owner Quick Guide

Start here first for the safest next-step summary before the deeper medication detail.

Used for:

For the treatment of infections in dogs and cats associated with bacteria susceptible to marbofloxacin.

Dosing note:

Exact dosing depends on your pet's species, weight, and health status. Use your veterinarian's instructions for the exact dose and schedule.

What to watch for:

  • Fever (1 reports)
  • Epidermal collarette (1 reports)
  • Elevated total bilirubin (1 reports)

When to call the vet:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
  • Facial swelling or hives.
  • Blood in vomit or stool.

Regulatory restrictions are shown in Vet View.

What to tell or ask your vet today:

  • Is this medicine the right fit for my pet’s current symptoms?
  • Which warning signs mean I should call back right away?
  • How should I handle missed doses or refusal to take the medicine?
Major cautions & emergency warning signs

Side effects to monitor:

  • Fever
  • Epidermal collarette
  • Elevated total bilirubin

Most reported reactions:

  • Fever (1 reports)
  • Epidermal collarette (1 reports)
  • Elevated total bilirubin (1 reports)

Emergency warning signs:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.

Quick Facts

Official label facts first, then secondary summaries. Marketing content is separated below.

Species: Both
Manufacturer: Multiple FDA labelers
Form: Chewable Tablets, Tablet
Identifiers:
ANADA: 200586 ANADA: 200733 ANADA: 200736 ANADA: 200761 NADA: 141151 NADA: 141598 NDC Package: 11695-7010-1 NDC Package: 11695-7010-2 NDC Package: 11695-7011-1 NDC Package: 11695-7011-2 NDC Package: 11695-7012-1 NDC Package: 11695-7013-1 NDC Package: 13612-0033-0 NDC Package: 13612-0033-1 NDC Package: 17033-013-10 NDC Package: 17033-013-25 NDC Package: 17033-014-10 NDC Package: 17033-014-25 NDC Package: 17033-015-50 NDC Package: 17033-016-50
Source metadata:

Warnings / Contraindications

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extra-label use of this drug in food-producing animals.

  • High: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extra-label use of this drug in food-producing animals.
Source metadata:

Adverse Reactions

Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.

Tap or hover a reaction to see what it means in plain language.

Tracked signals
32
Reported cases
32
Serious reports
27
Species represented
2
Grouped by Body System
Digestive (2) · Diarrhea, Bloody diarrhoea Behavior (2) · Behavioral disorder (unspecified), Anxiety Other (28) · Glucosuria, Fever, Epidermal collarette
Most Reported Reactions
Reaction Body system Cases Species Serious cases
Other 1 Cat 1
Other 1 Dog 1
Other 1 Cat 1
Other 1 Cat 1
Other 1 Cat 1
Other 1 Dog 1
Other 1 Cat 1
Other 1 Cat 1

Species coverage: Cat (17) Dog (15)

View detailed reaction table
Reaction Body system Species Seriousness Frequency Reports
Other Cat Non-serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Other Cat Non-serious - 1
Other Cat Serious - 1
Other Cat Non-serious - 1
Other Cat Non-serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Digestive Cat Serious - 1
Other Dog Serious - 1
Other Cat Non-serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Digestive Dog Serious - 1
Behavior Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Behavior Cat Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Source metadata:

Documents

Owner handouts and official technical documents open on-page first, with the original source still one click away.

Owner handouts

0
No owner handouts linked yet.

Official label / PI

0
No official label or package insert links yet.

SPL

22

FOI

7

Cronoquin™ Tablets

SPL · SPL

FDA Structured Product Label

Cronoquin™ Tablets

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Cronus Pharma Specialities India Private Ltd.
ANADA
200-761
Status
RX
Form
Tablet
Route
Oral
Composition / specifications
25 mg, 50 mg, 100 mg, or 200 mg marbofloxacin per tablet

Dogs and cats

Indication

For the treatment of infections in dogs and cats associated with bacteria susceptible to marbofloxacin.

Dosage

1.25 mg per pound (/lb) of body weight once daily, but may be increased to 2.5 mg/lb of body weight once daily.

Marbofloxacin

SPL · SPL

FDA Structured Product Label

Marbofloxacin

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
ZYVET AH, Inc.
ANADA
200-736
Status
RX
Form
Tablet
Route
Oral
Species
Dog, No Use Class Stated Or Implied • Cat, No Use Class Stated Or Implied
Composition / specifications
25 mg, 50 mg, 100 mg, or 200 mg marbofloxacin per tablet

Dogs and cats

Indication

For the treatment of infections in dogs and cats associated with bacteria susceptible to marbofloxacin.

Dosage

The recommended dosage for oral administration to dogs and cats is 1.25 mg marbofloxacin per lb of body weight once daily, but the dosage may be safely increased to 2.5 mg/lb. For the treatment of skin and soft tissue infections, Marbofloxacin tablets should be given for 2-3 days beyond the cessation of clinical signs for a maximum of 30 days. For the treatment of urinary tract infections, Marbofloxacin tablets should be administered for at least 10 days. If no improvement is noted within 5 days, the diagnosis should be re-evaluated and a different course of therapy considered.

Marbofloxacin Chewable Tablets

SPL · SPL

FDA Structured Product Label

Marbofloxacin Chewable Tablets

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Felix Pharmaceuticals Pvt. Ltd.
ANADA
200-733
Status
RX
Form
Chewable Tablets
Route
Oral
Species
Dog, No Use Class Stated Or Implied • Cat, No Use Class Stated Or Implied
Composition / specifications
25 mg, 50 mg, 100 mg, or 200 mg marbofloxacin per tablet

Dogs and cats

Indication

For the treatment of infections in dogs and cats associated with bacteria susceptible to marbofloxacin.

Dosage

The recommended dosage for oral administration to dogs and cats is 1.25 mg marbofloxacin per lb of body weight once daily, but the dosage may be safely increased to 2.5 mg/lb. For the treatment of skin and soft tissue infections, Marbofloxacin Chewable Tablets should be given for 2-3 days beyond the cessation of clinical signs for a maximum of 30 days. For the treatment of urinary tract infections, Marbofloxacin Chewable Tablets should be administered for at least 10 days. If no improvement is noted within 5 days, the diagnosis should be re-evaluated and a different course of therapy considered.

Marboquin™

SPL · SPL

FDA Structured Product Label

Marboquin™

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Dechra Veterinary Products LLC
ANADA
200-586
Status
RX
Form
Tablet
Route
Oral
Species
Dog, No Use Class Stated Or Implied • Cat, No Use Class Stated Or Implied
Composition / specifications
25 mg, 50 mg, 100 mg, and 200 mg

Dogs and cats

Indication

For the treatment of infections in dogs and cats associated with bacteria susceptible to marbofloxacin.

Dosage

The recommended dosage for oral administration to dogs and cats is 1.25 mg marbofloxacin per lb of body weight once daily, but the dosage may be safely increased to 2.5 mg/lb.

For the treatment of skin and soft tissue infections, Marboquin™ tablets should be given for 2-3 days beyond the cessation of clinical signs for a maximum of 30 days.

For the treatment of urinary tract infections, Marboquin™ tablets should be administered for at least 10 days. If no improvement is noted within 5 days, the diagnosis should be re-evaluated and a different course of therapy considered.

Zeniquin®

SPL · SPL

FDA Structured Product Label

Zeniquin®

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Zoetis Inc.
NADA
141-151
Status
RX
Form
Tablet
Route
Oral
Species
Dog, No Use Class Stated Or Implied • Cat, No Use Class Stated Or Implied
Composition / specifications
Each tablet contains either 25, 50, 100, or 200 milligrams of marbofloxacin.

Dogs

Indication
For the treatment of infections in dogs associated with bacteria susceptible to marbofloxacin.
Dosage
1.25 milligrams per pound of body weight once daily, but may be increased to 2.5 milligrams per pound of body weight once daily.
Limitations
Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extra-label use of this drug in food-producing animals.

Cats

Indication

For the treatment of infections in cats associated with bacteria susceptible to marbofloxacin.

Dosage
1.25 milligrams per pound of body weight once daily, but may be increased to 2.5 milligrams per pound of body weight once daily.
Limitations
Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extra-label use of this drug in food-producing animals.

Marbofloxacin SPL

SPL · Structured Product Label

FDA Structured Product Label XML for Marbofloxacin. Use the source link for the full official labeling record.

Marbofloxacin SPL

SPL · Structured Product Label

FDA Structured Product Label XML for Marbofloxacin. Use the source link for the full official labeling record.

Marbofloxacin SPL

SPL · Structured Product Label

FDA Structured Product Label XML for Marbofloxacin. Use the source link for the full official labeling record.

Marbofloxacin SPL

SPL · Structured Product Label

FDA Structured Product Label XML for Marbofloxacin. Use the source link for the full official labeling record.

MARBOFLOXACIN SPL

SPL · Structured Product Label

FDA Structured Product Label XML for MARBOFLOXACIN. Use the source link for the full official labeling record.

Marbofloxacin SPL

SPL · Structured Product Label

FDA Structured Product Label XML for Marbofloxacin. Use the source link for the full official labeling record.

Zeniquin SPL

SPL · Structured Product Label

FDA Structured Product Label XML for Zeniquin. Use the source link for the full official labeling record.

DELAQUIN SPL

SPL · Structured Product Label

FDA Structured Product Label XML for DELAQUIN. Use the source link for the full official labeling record.

FluoroFlox SPL

SPL · Structured Product Label

FDA Structured Product Label XML for FluoroFlox. Use the source link for the full official labeling record.

Marboquin SPL

SPL · Structured Product Label

FDA Structured Product Label XML for Marboquin. Use the source link for the full official labeling record.

Marbofloxacin SPL

SPL · Structured Product Label

FDA Structured Product Label XML for Marbofloxacin. Use the source link for the full official labeling record.

Marbofloxacin SPL

SPL · Structured Product Label

FDA Structured Product Label XML for Marbofloxacin. Use the source link for the full official labeling record.

Marbofloxacin SPL

SPL · Structured Product Label

FDA Structured Product Label XML for Marbofloxacin. Use the source link for the full official labeling record.

X SPL

SPL · Structured Product Label

FDA Structured Product Label XML for X. Use the source link for the full official labeling record.

MARBOFLOXACIN SPL

SPL · Structured Product Label

FDA Structured Product Label XML for MARBOFLOXACIN. Use the source link for the full official labeling record.

MARBOFLOXACIN SPL

SPL · Structured Product Label

FDA Structured Product Label XML for MARBOFLOXACIN. Use the source link for the full official labeling record.

Marbofloxacin SPL

SPL · Structured Product Label

FDA Structured Product Label XML for Marbofloxacin. Use the source link for the full official labeling record.

FOI Summary oA 200-761 Approved January 29, 2026.pdf

FOI · FOI

FOI Summary oA 200-736 Approved January 13, 2023.pdf

FOI · FOI

FOI Summary oA 200-733 Approved January 12, 2023.pdf

FOI · FOI

FOI Summary oA 200-586 Approved March 23, 2020.pdf

FOI · FOI

ucm117199.pdf

FOI · FOI

ucm117196.pdf

FOI · FOI

FOI Summary oN 141-598 Approved April 10 2025_ceg_ef.pdf

FOI · FOI summary

Veterinary reference (advanced)

Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.

At a Glance

Quick facts and links to official labeling and safety signals.

Data freshness
  • Storefront facts: Source Roxee | Refreshed May 5, 2026, 10:00 AM UTC
    The storefront fact projection used for browse cards and quick facts.
  • Animal Drugs @ FDA: Source FDA | Refreshed May 5, 2026, 10:00 AM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed May 5, 2026, 10:00 AM UTC
    Package/product NDCs from FDA’s electronic listing directory (XLS).
  • openFDA reaction terms: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC
Official (FDA)
Identity: Generic ingredient • FDA branded products available
Official FDA brands: DELAQUIN FluoroFlox MARBOFLOXACIN Marbofloxacin Marboquin X Zeniquin
Manufacturer mapping: Multiple FDA labelers
Case-reported brands (openFDA): MSK
Catalog species: Both FDA-labeled species: Cat, Dog
Rx/OTC: RX
Form/route: Chewable Tablets, Tablet Oral
Applications: ANADA 200-761 • ANADA 200-736 • ANADA 200-733 • ANADA 200-586 • NADA 141-151
NDC: Packages 11695-7010-1 11695-7010-2 11695-7011-1 11695-7011-2 11695-7012-1 11695-7013-1 Products 11695 13612 17033 46066 48087 51927
Documents: 6 (FOI: 6) • SPL: 5 Label highlights Official documents
Safety (openFDA)
Top reactions: Dog 35 Cat 3 View
Case summaries: 7 (showing 7) View
openFDA reports are unverified and do not prove causation.

Explore
Linked using: Fda_Label (0.95), Usage_Inferred (0.78)

Diagnosis Codes
ICD10_CM: H60.90
Otitis externa, unspecified ear

Counseling and Monitoring Highlights

Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.

Owner-facing counseling points
  • Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extra-label use of this drug in food-producing animals. (Contraindication, High)
Top reaction signals
Fever (1) Epidermal collarette (1) Elevated total bilirubin (1) Elevated symmetrical dimethylarginine (1) Elevated serum alkaline phosphatase (1) Elevated lipase (1) Elevated creatinine (1) Elevated aspartate aminotransferase (1)

Identifiers & Packages

Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.

Identifiers
ANADA: 200586 ANADA: 200733 ANADA: 200736 ANADA: 200761 NADA: 141151 NADA: 141598 NDC Package: 11695-7010-1 NDC Package: 11695-7010-2 NDC Package: 11695-7011-1 NDC Package: 11695-7011-2 NDC Package: 11695-7012-1 NDC Package: 11695-7013-1 NDC Package: 13612-0033-0 NDC Package: 13612-0033-1 NDC Package: 17033-013-10 NDC Package: 17033-013-25 NDC Package: 17033-014-10 NDC Package: 17033-014-25 NDC Package: 17033-015-50 NDC Package: 17033-016-50 NDC Package: 46066-171-32 NDC Package: 46066-171-33 NDC Package: 46066-173-32 NDC Package: 46066-173-33
Package NDC Product NDC Form / Route Status
11695-7010-1 11695 -
11695-7010-2 11695 -
11695-7011-1 11695 -
11695-7011-2 11695 -
11695-7012-1 11695 -
11695-7013-1 11695 -
13612-0033-0 13612 -
13612-0033-1 13612 -
17033-013-10 17033 -
17033-013-25 17033 -
17033-014-10 17033 -
17033-014-25 17033 -
17033-015-50 17033 -
17033-016-50 17033 -
46066-171-32 46066 -
46066-171-33 46066 -
46066-173-32 46066 -
46066-173-33 46066 -
46066-175-31 46066 -
46066-176-31 46066 -

Enriched Documents

Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.

  • Marbofloxacin SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • Marbofloxacin SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • Marbofloxacin SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • Marbofloxacin SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • MARBOFLOXACIN SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • Marbofloxacin SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • Zeniquin SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • DELAQUIN SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • FluoroFlox SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • Marboquin SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • Marbofloxacin SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • Marbofloxacin SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • Marbofloxacin SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • X SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • MARBOFLOXACIN SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • MARBOFLOXACIN SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • Marbofloxacin SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • FOI Summary oA 200-761 Approved January 29, 2026.pdf • FOI summary • Official • Feb. 2, 2026
    FDA FOI summary for application 200761
  • FOI Summary oN 141-598 Approved April 10 2025_ceg_ef.pdf • FOI summary • Official • June 3, 2025
    FDA FOI summary for application 141598
  • FOI Summary oA 200-736 Approved January 13, 2023.pdf • FOI summary • Official • Feb. 1, 2023
    FDA FOI summary for application 200736
  • FOI Summary oA 200-733 Approved January 12, 2023.pdf • FOI summary • Official • Feb. 1, 2023
    FDA FOI summary for application 200733
  • FOI Summary oA 200-586 Approved March 23, 2020.pdf • FOI summary • Official • April 1, 2020
    FDA FOI summary for application 200586
  • ucm117196.pdf • FOI summary • Official • Feb. 12, 2019
    FDA FOI summary for application 141151
  • ucm117199.pdf • FOI summary • Official • Feb. 12, 2019
    FDA FOI summary for application 141151

Data Sources & Change Log

Every non-trivial field is expected to include provenance and update timestamps.

Official 68 Clinical 1 Manufacturer 0 Marketing 0
Current Field Facts
  • side_effects: Top reported reactions (openFDA): Vomiting, Lethargy (see also Central nervous system depression in 'Neurological'), Lack of efficacy - NOS, Anorexia, Other ab… (Clinical, 2026-04-11)
  • contraindications: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extra-label use of this drug in food-producing … (Official, 2026-04-12)
  • contraindications: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extra-label use of this drug in food-producing … (Official, 2026-04-11)
  • contraindications: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extra-label use of this drug in food-producing … (Official, 2026-02-12)
  • dosage_forms: Chewable tablet (Official, 2026-05-05)
  • dosage_forms: Chewable tablet (Official, 2026-05-03)
  • dosage_forms: Chewable tablet (Official, 2026-05-02)
  • dosage_forms: Chewable tablet (Official, 2026-04-29)
  • dosage_forms: Chewable tablet (Official, 2026-04-28)
  • dosage_forms: Chewable tablet (Official, 2026-04-27)
  • dosage_forms: Chewable tablet (Official, 2026-04-26)
  • dosage_forms: Chewable tablet (Official, 2026-04-25)
  • dosage_forms: Chewable tablet (Official, 2026-04-22)
  • indications: For the treatment of infections in dogs and cats associated with bacteria susceptible to marbofloxacin. Zeniquin ™ (marbofloxacin) tablets are indicated for th… (Official, 2026-05-05)
  • indications: For the treatment of infections in dogs and cats associated with bacteria susceptible to marbofloxacin. Zeniquin ™ (marbofloxacin) tablets are indicated for th… (Official, 2026-05-03)
  • indications: For the treatment of infections in dogs and cats associated with bacteria susceptible to marbofloxacin. Zeniquin ™ (marbofloxacin) tablets are indicated for th… (Official, 2026-05-02)
  • indications: For the treatment of infections in dogs and cats associated with bacteria susceptible to marbofloxacin. Zeniquin ™ (marbofloxacin) tablets are indicated for th… (Official, 2026-04-29)
  • indications: For the treatment of infections in dogs and cats associated with bacteria susceptible to marbofloxacin. Zeniquin ™ (marbofloxacin) tablets are indicated for th… (Official, 2026-04-28)
  • indications: For the treatment of infections in dogs and cats associated with bacteria susceptible to marbofloxacin. Zeniquin ™ (marbofloxacin) tablets are indicated for th… (Official, 2026-04-27)
  • indications: For the treatment of infections in dogs and cats associated with bacteria susceptible to marbofloxacin. Zeniquin ™ (marbofloxacin) tablets are indicated for th… (Official, 2026-04-26)
Recent Revisions
  • side_effects updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
  • side_effects updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
  • side_effects updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields

FDA Products & Applications (Animal Drugs @ FDA)

Official sponsor/proprietary-name/application-status records linked by active ingredient.

Product Sponsor Application Status Published
Cronoquin™ Tablets
RX
Marbofloxacin
Tablet Oral
Cronus Pharma Specialities India Private Ltd. ANADA 200-761 Approved Feb 2, 2026
Marbofloxacin
RX
Marbofloxacin
Tablet Oral
ZYVET AH, Inc. ANADA 200-736 Approved Feb 1, 2023
Marbofloxacin Chewable Tablets
RX
Marbofloxacin
Chewable Tablets Oral
Felix Pharmaceuticals Pvt. Ltd. ANADA 200-733 Approved Feb 1, 2023
Marboquin™
RX
Marbofloxacin
Tablet Oral
Dechra Veterinary Products LLC ANADA 200-586 Approved Apr 1, 2020
Zeniquin®
RX
Marbofloxacin
Tablet Oral
Zoetis Inc. NADA 141-151 Approved Feb 12, 2019

Data source: FDA Animal Drugs @ FDA (public search export).

What It's For (FDA Label Highlights)

Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.

Composition / specifications
25 mg, 50 mg, 100 mg, or 200 mg marbofloxacin per tablet
Dogs and cats
Indication

For the treatment of infections in dogs and cats associated with bacteria susceptible to marbofloxacin.

Dosage

1.25 mg per pound (/lb) of body weight once daily, but may be increased to 2.5 mg/lb of body weight once daily.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied • Cat, No Use Class Stated Or Implied
Composition / specifications
25 mg, 50 mg, 100 mg, or 200 mg marbofloxacin per tablet
Dogs and cats
Indication

For the treatment of infections in dogs and cats associated with bacteria susceptible to marbofloxacin.

Dosage

The recommended dosage for oral administration to dogs and cats is 1.25 mg marbofloxacin per lb of body weight once daily, but the dosage may be safely increased to 2.5 mg/lb. For the treatment of skin and soft tissue infections, Marbofloxacin tablets should be given for 2-3 days beyond the cessation of clinical signs for a maximum of 30 days. For the treatment of urinary tract infections, Marbofloxacin tablets should be administered for at least 10 days. If no improvement is noted within 5 days, the diagnosis should be re-evaluated and a different course of therapy considered.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied • Cat, No Use Class Stated Or Implied
Composition / specifications
25 mg, 50 mg, 100 mg, or 200 mg marbofloxacin per tablet
Dogs and cats
Indication

For the treatment of infections in dogs and cats associated with bacteria susceptible to marbofloxacin.

Dosage

The recommended dosage for oral administration to dogs and cats is 1.25 mg marbofloxacin per lb of body weight once daily, but the dosage may be safely increased to 2.5 mg/lb. For the treatment of skin and soft tissue infections, Marbofloxacin Chewable Tablets should be given for 2-3 days beyond the cessation of clinical signs for a maximum of 30 days. For the treatment of urinary tract infections, Marbofloxacin Chewable Tablets should be administered for at least 10 days. If no improvement is noted within 5 days, the diagnosis should be re-evaluated and a different course of therapy considered.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied • Cat, No Use Class Stated Or Implied
Composition / specifications
25 mg, 50 mg, 100 mg, and 200 mg
Dogs and cats
Indication

For the treatment of infections in dogs and cats associated with bacteria susceptible to marbofloxacin.

Dosage

The recommended dosage for oral administration to dogs and cats is 1.25 mg marbofloxacin per lb of body weight once daily, but the dosage may be safely increased to 2.5 mg/lb.

For the treatment of skin and soft tissue infections, Marboquin™ tablets should be given for 2-3 days beyond the cessation of clinical signs for a maximum of 30 days.

For the treatment of urinary tract infections, Marboquin™ tablets should be administered for at least 10 days. If no improvement is noted within 5 days, the diagnosis should be re-evaluated and a different course of therapy considered.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied • Cat, No Use Class Stated Or Implied
Composition / specifications
Each tablet contains either 25, 50, 100, or 200 milligrams of marbofloxacin.
Dogs
Indication
For the treatment of infections in dogs associated with bacteria susceptible to marbofloxacin.
Dosage
1.25 milligrams per pound of body weight once daily, but may be increased to 2.5 milligrams per pound of body weight once daily.
Limitations
Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extra-label use of this drug in food-producing animals.
Cats
Indication

For the treatment of infections in cats associated with bacteria susceptible to marbofloxacin.

Dosage
1.25 milligrams per pound of body weight once daily, but may be increased to 2.5 milligrams per pound of body weight once daily.
Limitations
Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extra-label use of this drug in food-producing animals.

FDA page: Open in Animal Drugs @ FDA

Usage

For the treatment of infections in dogs associated with bacteria susceptible to marbofloxacin. For the treatment of infections in cats associated with bacteria susceptible to marbofloxacin. For the treatment of otitis externa associated with susceptible strains of yeast ( Malassezia pachydermatis ) and bacteria ( Staphylococcus pseudintermedius ) in dogs.

Source: FDA Animal Drugs @ FDA • Reference

Contraindications

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extra-label use of this drug in food-producing animals.

Top Reported Reactions (openFDA)

De-duplicated reaction terms grouped by body system from FDA openFDA reports (not verified; does not prove causation).

Digestive
Diarrhea (1) • Cat Bloody diarrhoea (1) • Dog

Showing top 5 for Digestive.

Behavior
Behavioral disorder (1) • Dog Anxiety (1) • Cat

Showing top 5 for Behavior.

Other
Glucosuria (1) • Cat Fever (1) • Cat Epidermal collarette (1) • Dog Elevated total bilirubin (1) • Cat Elevated symmetrical dimethylarginine (1) • Cat
Show more (23)
Elevated serum alkaline phosphatase (1) • Cat Elevated lipase (1) • Dog Elevated globulins (1) • Cat Elevated creatinine (1) • Cat Elevated blood urea nitrogen (1) • Cat Elevated betahydroxybutyrate (1) • Cat Elevated aspartate aminotransferase (1) • Cat Elevated alanine aminotransferase (1) • Cat Discomfort NOS (1) • Dog Dermal thickening (1) • Dog Dental disease (1) • Cat Death by euthanasia (1) • Dog Death (1) • Dog Cough (1) • Dog Constipation (1) • Dog Cholangitis (1) • Cat Barking (1) • Dog Bacterial skin infection NOS (1) • Dog Aspiration pneumonia (1) • Dog Anaemia NOS (1) • Dog Abnormal ultrasound finding (1) • Cat Abdominal pain (1) • Dog Abdominal mass (1) • Cat

Showing top 5 for Other.

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Adverse Event Case Summaries (openFDA)

These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.

Dog, Boxer (German Boxer), Female, 8 year, 27.3 kilogram • Drug: MSK, Tablet, Oral, Dose: 100 Milligram per animal, Frequency: 1 per day • Reactions: Bloody diarrhoea, Elevated lipase, Pancreatitis NOS, Haemorrhagic gastroenteritis, Intentional misuse • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-075293
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Female
  • Age: 8.00 Year
  • Weight: 27.300 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Tablet
  • Dose: 100 Milligram per animal
  • Frequency: 1 per day
Reactions Reported:
Bloody diarrhoea Elevated lipase Pancreatitis NOS Haemorrhagic gastroenteritis Intentional misuse
Outcomes: Ongoing

Dog, ['Retriever - Labrador', 'Dog (unknown)'], Female, 14 year, 26.76 kilogram • Drug: MSK, Tablet, Oral • Reactions: Skin ulcer, Bacterial skin infection NOS, Lack of efficacy (bacteria) - NOS • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-074110
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Female
  • Age: 14.00 Year
  • Weight: 26.760 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Tablet
Reactions Reported:
Skin ulcer Bacterial skin infection NOS Lack of efficacy (bacteria) - NOS
Outcomes: Ongoing

Dog, ['Hound (unspecified)', 'Dog (unknown)'], Male, 14.5 year, 35.83 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Aspiration pneumonia, Lack of efficacy - NOS, Medication error NOS, Anaemia NOS, Mass NOS… • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-074245
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Age: 14.50 Year
  • Weight: 35.830 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Unassigned
Reactions Reported:
Aspiration pneumonia Lack of efficacy - NOS Medication error NOS Anaemia NOS Mass NOS Skin ulcer Urine leakage Limb weakness Proprioception deficit Walking difficulty Barking Anxiety Urinary tract infection Diarrhea Cough Pain NOS
Outcomes: Ongoing

Dog, ['Terrier (unspecified)', 'Dog (unknown)'], Male, 9 year, 18.14 kilogram • Drug: MSK, Unknown • Reactions: Behavioral disorder (unspecified), Epidermal collarette, Hepatic toxicosis, Dermal thickening, Pyoderma… • Outcome: Died

  • Report ID: USA-USFDACVM-2025-US-074320
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Age: 9.00 Year
  • Weight: 18.140 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
Reactions Reported:
Behavioral disorder (unspecified) Epidermal collarette Hepatic toxicosis Dermal thickening Pyoderma Joint swelling Local swelling Skin ulcer Tiredness (lethargy) Itching Hair loss NOS Death Inappetence
Outcomes: Died

Dog, ['Terrier (unspecified)', 'Dog (unknown)'], Male, 9 year, 18.14 kilogram • Drug: MSK, Unknown • Reactions: Behavioral disorder (unspecified), Epidermal collarette, Hepatic toxicosis, Dermal thickening, Pyoderma… • Outcome: Died

  • Report ID: USA-USFDACVM-2025-US-068424
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Age: 9.00 Year
  • Weight: 18.140 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
Reactions Reported:
Behavioral disorder (unspecified) Epidermal collarette Hepatic toxicosis Dermal thickening Pyoderma Joint swelling Local swelling Skin ulcer Tiredness (lethargy) Itching Hair loss NOS Death Inappetence
Outcomes: Died

Cat, Domestic Shorthair, Female, 11 year, 5.806 kilogram • Drug: MSK, Tablet, Oral, Dose: 1 dose per animal, Frequency: 1 per day • Reactions: Fever, Lack of efficacy - NOS • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-065991
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Female
  • Age: 11.00 Year
  • Weight: 5.806 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Tablet
  • Dose: 1 dose per animal
  • Frequency: 1 per day
Reactions Reported:
Fever Lack of efficacy - NOS
Outcomes: Ongoing

Cat, Domestic Mediumhair, Female, 11 year, 3.9 kilogram • Drug: MSK, Unknown • Reactions: Elevated betahydroxybutyrate • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2025-US-063885
  • Serious AE: No
  • Treated For AE: No
  • Sex: Female
  • Age: 11.00 Year
  • Weight: 3.900 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
Reactions Reported:
Elevated betahydroxybutyrate
Outcomes: Outcome Unknown

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Overdose Information

No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.

Storage & Handling

No approved storage guidance is linked yet for this ingredient. Use manufacturer packaging and veterinary guidance for handling/storage.

Share Your Thoughts

Let others know your experience or advice regarding this medication.

This medication has not been reviewed by a veterinarian yet.